Korean J Hematol 2012; 47(3):
Published online September 25, 2012
https://doi.org/10.5045/kjh.2012.47.3.225
© The Korean Society of Hematology
1Department of Laboratory Medicine, Gachon University Gil Medical Center, Incheon, Korea.
2Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Correspondence to : Correspondence to Jeong Yeal Ahn, M.D. Department of Laboratory Medicine, Gachon University Gil Medical Center, 1198, Guwol-dong, Namdong-gu, Incheon 405-706, Korea. Tel: +82-32-460-3863, Fax: +82-32-460-3415, jyahn@gilhospital.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Radioiodine is regularly used in the treatment of thyroid cancer to eliminate residual malignant tissue after thyroidectomy and to treat metastasis. Because of the low dose of radioiodine used to treat thyroid cancer patients, leukemia is an uncommon complication of exposure to radioiodine. Here, we present a patient who developed therapy-related acute myeloid leukemia with inv(16)(p13.1q22);
Keywords Radioiodine, Thyroid cancer, Acute myeloid leukemia,
Korean J Hematol 2012; 47(3): 225-228
Published online September 25, 2012 https://doi.org/10.5045/kjh.2012.47.3.225
Copyright © The Korean Society of Hematology.
Ji Hun Jeong1, Jeong Yeal Ahn1*, Soon Ho Park1, Mi Jung Park1, Kyung Hee Kim1, and Jun Shik Hong2
1Department of Laboratory Medicine, Gachon University Gil Medical Center, Incheon, Korea.
2Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Correspondence to:Correspondence to Jeong Yeal Ahn, M.D. Department of Laboratory Medicine, Gachon University Gil Medical Center, 1198, Guwol-dong, Namdong-gu, Incheon 405-706, Korea. Tel: +82-32-460-3863, Fax: +82-32-460-3415, jyahn@gilhospital.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Radioiodine is regularly used in the treatment of thyroid cancer to eliminate residual malignant tissue after thyroidectomy and to treat metastasis. Because of the low dose of radioiodine used to treat thyroid cancer patients, leukemia is an uncommon complication of exposure to radioiodine. Here, we present a patient who developed therapy-related acute myeloid leukemia with inv(16)(p13.1q22);
Keywords: Radioiodine, Thyroid cancer, Acute myeloid leukemia,
Morphologic and cytogenetic study.
Hee Sue Park
Blood Res 2024; 59():Saba Manoochehrabadi, Morteza Talebi, Hossein Pashaiefar, Soudeh Ghafouri‑Fard, Mohammad Vaezi, Mir Davood Omrani and Mohammad Ahmadvand
Blood Res 2024; 59():Jung Hwan Lee, Hee Young Ju, Ju Kyung Hyun, So Jin Kim, Hee Won Cho, Jae Kyung Lee, Ji Won Lee, Ki Woong Sung, Keon Hee Yoo
Blood Res 2023; 58(4): 181-186
Morphologic and cytogenetic study.